Massachussetts Patent of the Month – April 2025
Crosswalk Therapeutics has unveiled a significant advancement in enzyme replacement therapy with its newly patented invention, “Human alpha-galactosidase variants” (U.S. Patent No. 12286655). This innovation aims to improve treatment outcomes for individuals suffering from Fabry disease, a rare genetic disorder that leads to the accumulation of harmful substances in the body.
Enhanced Stability and Efficacy in Treatment
The patented engineered human alpha-galactosidase polypeptides exhibit improved thermostability, serum stability, and cellular uptake. They also demonstrate stability under both acidic and basic conditions, reduced immunogenicity, and enhanced removal of globotriaosylceramide from cells. These enhancements could lead to more effective and reliable treatments for Fabry disease patients.
Strategic Acquisition Bolsters Development
In a strategic move to advance these therapies, Crosswalk Therapeutics acquired investigational Fabry disease compounds from Codexis. This acquisition, finalized in July 2024, positions Crosswalk to leverage its expertise in rare diseases to bring these promising treatments closer to clinical application.(Codexis, Inc.)
The combination of Crosswalk’s innovative enzyme technology and the acquired compounds holds the potential to significantly improve the quality of life for those affected by Fabry disease. As development progresses, this breakthrough could mark a new era in the treatment of lysosomal storage disorders.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
